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Review of referral for lung transplantation in one CF centre 
K. Mohan, C. McManus, M.J. Ledson, M.J. Walshaw 
Regional Adult CF Unit, The Cardiottu~racic Centre, Liverpool, UK 
Introduction. Lung transplantation prolongs s~arvival in end stage lung disease. 
However selection of the appropriate candidate mad t iming of referral for lung 
transplantation remains difficult given the unpredictable nature of CF disease and 
the l imited availabil ity of donor organs. The purpose of the study was to analyse our 
lung transplantation referral policies mad evaluate outcomes for patients referred for 
lung transplantation. 
Mettu)ds. Of 219 patients who attended our adult unit from 1993 2004, 54 (25%) 
have died. The mortality rate in B cenc~zepacia p tients (who are not suitable for 
transplantation) was much greater (28/44 vs 26/175, Z 9 45.03, P<0.C()I). We 
reviewed all referrals for lung transplantation 
Results. 22 patients were referred: all were hypoxaemic with an FEV1% predicted 
< 30%. 19 patients were el igible for study. During this period 5 (26%) were 
transplanted, 2 (11%) declined transplant, mad 10 (52%) of the remaining 12 have 
died on the wait ing list. In those transplanted the average wait ing t ime was 11 
months (range 4 to 17 months). Patients who have died survived for an average of 
13 months (range 7 to 21 ) await ing transplant. There were no significant differences 
ha clinical parameters at the t ime of referral between those who died wait ing and 
those who survived to transplantation. Among the transplanted group 3 are alive at 
an average 16 months post transplant (range 1 to 36 months) whereas 2patients died 
5 months mad 2 years post transplantation from respiratory and renal fai lure 
respectively. 
Conclusions. Al l  patients were appropriately referred in accordance with the 
international guidelines on lung transplantation. Death rate on the wait ing list 
continues to be high and there is an urgent need for donor organs to improve 
mottality from end stage CF lung disease. 
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Bronhic responsivity in cysfic fibrosis 
I. Popal,Z. Popa ~, L. Pop 1, C. Bunu ~ 
iClinic H Pediatrics-University of Medicine a~M Pharmacy, 2CF Centre, Sphisiology 
Department - University of Medicine a~ul Pharmacy -~misoara, Romania 
The aim was the evaluation of bronhic responsivity (BR) ha CF patients. We 
observed the fol lowing situations: patients with CF (11 cases, aged 6 25 years), 
patients with CF and bronchial asthma (4 cases, aged 6 10 years), patients with CF 
and ABPA (2 cases, 21 mad 32 years). BR was performed flarough bronchial 
provceative tests: inhalator administration of metacholin ( i f  FEV I> 80 %) or [~2 
agonist ( i f  FEV1 80 %) of predicted value. We followed up the dose of met acholin 
which induced the decrease of FEV1 with 20 % comparative to the control value 
(PC~0 ~ FEV1). The bronchodilatator (BD) test was considered positive when an 
increase of FEV1 > 15 % was found. Selectively, at patients with asthma we 
effectuated cutaneous tests and specific IgE antibody for Aspergillus fumigatus. 
Results. In the group with CF, 7 patients (aged 15 25 years) presented mixed 
moderate or severe ventilator dysfunction; 4 of them had positive BD test mad 3 had 
negative test. The other 4 patients of the same group (aged 6 13 years) had normal 
basal venti lometric parameters. Two of them presented positive bronchial  
pr ovceation test with metacholin for medium BR. In the group of the CF and asthma 
two presented moderate BR, one had normal ventilometric indexes mad one 
presented mild obstructive ventilator dysfunction with positive BD test. In these 
patients the cutaneous tests and the specific IgE antibody were negative. The cases 
with ABPA were confirmed flat ough cultures, cutaneous te ts and IgE specific. The 
evolution of these cases was towards severe mixed ventilator dysfunction with 
positive BD test. Conclusion. BR is a common phenomenon ha CF, with variations 
from one patient to another, that increases in t ime mad was present at all cl inical 
situations from our study. 
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Outcome in children after referral for lung kansplant 
M. Ratcliffe, K. Br ownlee, S. Conway 
Paediatric C F Unit, St James' Hospital, Leeds, UK 
The aim of this study was to detail the outcome of chi ldren attending a major CF 
centre fol lowing referral for lung transplant. Data collection from the records of 
patients considered for lung transplant from 1/95 to 10/04 included best annual 
FEV1 in the 5 years before referral, FEV1 at referral and annually after transplant, 
intensity of treatment in the year before referral, survival, cause of death. Rate of 
decline ha FEV1 was calculated by linear regression. 
Approximately 500 patients attended over the study period. Transplant was 
considered for 17 but rejected by 1 family. Mean age at referral 12 years, % 
predicted FEV1 29, % weight for height 88. ha year before referral mean rate of 
FEVldec l ine 7%, mean days of IV antibiotic treatment 68. Mean wait referral to 
assessment, 2.4 months. 1 child who was considered too il l and 1 who had a pyrexia 
of unknown origin were rejected. 5 children accepted to active and 9 to provisional 
list. Of  these 9, 2 improved and were taken off the list, 2 died, 3 transferred to active 
list. Mean t ime on provisional list, 21.7 months. 7 of 8 actively listed patients have 
had a transplant. Mean t ime l isting to transplant, 10.3 months. Mean t ime referral to 
transplant, 16.5 months.1 patient died 8 months after s~argery (Bcc infection). 
Kaplan Meier  survival analysis after transplant, 83% at 1 and 5 years. Mean FEV1 
% predicted at 1,2,3 years, 84%, 85%, 79%. 
For informed ecision making the results of the full pathway fol lowing referral from 
the CF centre are needed. This study shows the importance of ma accelerated decline 
ha lung function as ma indicator for eferral; the more rapid UK  assessment and 
treatment for paediatric patients; favour able 5 year survival data compared to other 
published reports. Lung transplant is a viable treatment strategy for children with 
end stage CF lung disease. 
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Cystic Fibrosis and tuberculosis a non-usual relafionship 
C. Gonzfilez l, I. Largo l, J. Lozmlo 9 
iUniversidad de Chile, 2HospitaI Roberto deI Rio, Santiago, Chile 
Tuberculosis (TBC) in Oystic Fibrosis (CF)  patients it has been reported as a fact 
of rare incidence, in our hospital pulmonary TBC has been diagnosed in one case, 
male patient 19 years old with severe CF, Shwachman (Shw) 30, Brasfield (Brasf) 
10, pulmonary ftmction(PF) with restriction and severe obstruction, non reversible. 
Chronically infected with Pseudomonas Aeruginosa (PA) since 1992 to 1999, 
monthly negatives specimens between 1999 mad 2003. Treatment: pancreatic 
enzymes, liposolubles vitamins, rhDNAsa, ursodeoxic61ico acid, Azitromicin, 
Salbutamol inh., diary physiotherapy, and antibiotics and hospitalizations i f
necessary. In May 2CO3 began with progressive deterioration in nutrition, 
pulmonary function and newly persistent with FA, Shw+Brasf low since 58 to 40. 
In Apri l  2CO4 we obtain two bacilccopies and Kcck positive specimens. The 
treatment begun ha May 2CO4 with isionacide, Rifanpicine, and pirazinamide. The 
baciloscopies were negative on the 20 m day and and the bacteriological specimens 
were negative on the fol lowing months, after two months his body weight increased 
over 2 kilograms. Commentary : the contact studies were negative. Conclusion: we  
have decided to investigate TBC ha CF patients with torpid evolution. 
